Tauopathy
Therapeutic area
Neurology
Rare disease
No
- Definition
- Neurodegenerative disorders involving deposition of abnormal tau protein isoforms (tau proteins) in neurons and glial cells in the brain. Pathological aggregations of tau proteins are associated with mutation of the tau gene on chromosome 17 in patients with alzheimer disease; dementia; parkinsonian disorders; progressive supranuclear palsy (supranuclear palsy, progressive); and corticobasal degeneration.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Tauopathy
- Alternative names
- tauopathy
- Therapeutic area
- Neurology
- All therapeutic areas
- Neurology
Sources for recorded values
- Severity
- Severe
- MONDO ID
- MONDO:0005574
- Parent condition
- MONDO:0005559
Related records
Broader conditions (8)
- Central nervous system disorder
- Disease
- Disease by body system or component
- Disease by developmental or physiological process
- Disease by molecular mechanism
- Human disease
- Nervous system disorder
- Neurodegenerative disease
Narrower conditions (23)
- Alzheimer disease
- Alzheimer disease 10
- Alzheimer disease 11
- Alzheimer disease 12
- Alzheimer disease 13
- Alzheimer disease 14
- Alzheimer disease 16
- Alzheimer disease 17
- Alzheimer disease 18
- Alzheimer disease 19
- Alzheimer disease 2
- Alzheimer disease 3
- Alzheimer disease 4
- Alzheimer disease 5
- Alzheimer disease 6
- Alzheimer disease 7
- Alzheimer disease 8
- Alzheimer disease type 1
- Alzheimer disease without neurofibrillary tangles
- Alzheimer disease, familial early-onset, with coexisting amyloid and prion pathology
Trials (73)
- [18F]NIDF PET Imaging in Tau-related Diseases
- 2-(1-{6-[(2-[F-18]Fluoroethyl) (Methyl)Amino]-2-naphthyl} Ethylidene) Malononitrile-PET for in Vivo Diagnose of Tauopathy in Unclassified Parkinsonism
- A 24-month Phase 1 Pilot Study of AADvac1 in Patients With Non Fluent Primary Progressive Aphasia
- A 24-weeks, Multi-center, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Donepezil Hydrochloride in Chinese Subjects With Severe Alzheimer's Disease
- A Bridging Study on Efficacy and Safety of [18F]Florbetaben PET for Diagnosis of Alzheimer Disease Subjects in Chinese Population
- A Double-Blind, Placebo-Controlled Safety and Efficacy Study of NA-831
- A Drug-Drug Interaction Study to Assess the CYP1A2 and CYP3A4 Interaction Potential of TEV-56286 (anle138b)
- A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease
- A First-in-Human Study of Single and Multiple Doses of anle138b in Healthy Subjects
- A First-in-Human Study to Assess Single Doses of APNmAb005 in Healthy Participants
- A Phase Ia/Ib, First-in-human (FIH) Study for Safety, Tolerability, Pharmacokinetics (PK), and Clinical Activity Evaluation of ADEL-Y01
- A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of Intravenously Administered BMS-986168 in Healthy Subjects
- A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)
- A Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease Dementia
- A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease Dementia
- A Study of LY3303560 in Participants With Early Symptomatic Alzheimer's Disease
- A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's Disease
- A Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of Inflammation
- A Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Subjects With Progressive Supranuclear Palsy (PSP)
- A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis
Drugs in development (1)
- Zagotenemab Phase 1